Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
34,530,294
-
Share change
-
+119,913
-
Total reported value
-
$116,365,282
-
Put/Call ratio
-
0%
-
Price per share
-
$3.37
-
Number of holders
-
91
-
Value change
-
+$265,376
-
Number of buys
-
40
-
Number of sells
-
43
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q2 2025
As of 30 Jun 2025,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
91 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,530,294 shares.
The largest 10 holders included
SR One Capital Management, LP, Logos Global Management LP, BlackRock, Inc., Frazier Life Sciences Management, L.P., Point72 Asset Management, L.P., TANG CAPITAL MANAGEMENT LLC, BAKER BROS. ADVISORS LP, Almitas Capital LLC, VANGUARD GROUP INC, and Driehaus Capital Management LLC.
This page lists
91
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.